Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects.
about
Future of coagulation factor replacement therapyPharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.New treatments in hemophilia: insights for the clinician.Molecular approaches for improved clotting factors for hemophilia.The hope and reality of long-acting hemophilia products.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.The future of hemostasis management.Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals.Advances in the treatment of inherited coagulation disorders.Investigational drugs for coagulation disorders.Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling.Novel products for haemostasis - current status.Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
P2860
Q26820824-D53C6098-C0BF-462B-AB47-6A090863A8E7Q34200694-75A22195-15F8-444B-88EC-F4AE1C9B0B71Q34548522-73BBA607-C7F9-4EDC-9BFC-C49D59C4FB07Q36612681-2BC16FBC-1D50-4261-9D41-6DFF373376C0Q37334700-4BA8FA7C-F8D7-43A0-BA30-BEF56D9418CFQ37990479-29E6951D-BA05-4495-968F-82BAC777C259Q38036746-18C93631-7813-4B67-86C2-ECDE39B32D73Q38056457-B5E41669-23F6-4163-8ED7-A4EEDB2E3573Q38079864-91AF5804-5224-4E24-8DBF-1E5EB6E300DEQ38100271-796469F6-FAE0-4521-BB37-53472EFB4BB3Q38106245-1B9D346E-247C-4D2E-9FDD-2C6053BCFA11Q38121644-6DCBC9DD-AB85-45F6-A5FC-8A73CCB475D1Q38206849-F461E4D8-D3F3-4F53-9DFD-A9D776A598C4Q38266890-B5C345F7-F904-43D1-8626-D5D165927643Q44051815-292874B4-CEB8-41E1-834F-D9CD83E8DFC5Q45857094-59BA8F2A-C917-4FE0-8722-DF4A816FAA02Q45886610-F3F0F6BB-D8F8-47F4-8AEF-7E27E65CA167
P2860
Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@en
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@nl
type
label
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@en
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@nl
prefLabel
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@en
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@nl
P2093
P2860
P1476
Safety and pharmacokinetics of ...... ose trial in healthy subjects.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2011.04344.X
P577
2011-07-01T00:00:00Z